West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report

A new $200 million term loan and $750 million revolver run to 2031, as $685.3 million of buybacks cut cash to $464.1 million.

Share
West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report

West Pharmaceutical's 10-Q, filed Thursday, carries $203.0 million of 2027 debt as long-term only because a refinancing closed on October 26, before the statements were issued. The maker of containment and delivery systems for injectable drugs has also spent $685.3 million on buybacks in the first nine months of 2026.

Two 2027 maturities, one new facility

The old debt was a $130.0 million term loan due July 2, 2027, and $73.0 million of 4.02% Series C notes due July 5, 2027. The prior quarter's 10-Q showed the same two maturities alongside a $500.0 million revolver.

The new agreement, with Bank of America as administrative agent, matures October 26, 2031. It pairs a $750 million revolver with a $200 million term loan, which replaced the $130.0 million loan. Quarterly term-loan payments of $1.25 million to $2.5 million start March 31, 2028.

The $73.0 million of Series C notes is slated for repayment on or about November 2, 2026, partly from the new loan. No make-whole premium applies. A leverage covenant caps net leverage at 3.50 to 1.0, rising for big acquisitions. The 8-K says proceeds may fund acquisitions and stock repurchases.

Buybacks drain the cash pile

West bought 2,424,121 shares for $685.3 million over nine months, an average $282.68 a share. Third-quarter buying was $231.0 million, or 663,511 shares, at an average $348.11. A new $1.0 billion authorization approved in February has no expiration date.

Cash fell to $464.1 million at September 30 from $791.3 million at year-end. Operating cash flow for the nine months was $403.4 million, down from $503.7 million a year earlier. Accounts receivable climbed to $748.2 million from $574.4 million, which the company ties to the timing of sales and customer collections.

The stock closed Thursday with a market value of $28.4 billion.

Sales and profit still growing

Third-quarter net sales rose 8.7% to $874.5 million, or 11.9% organically, and diluted earnings per share were $3.02. Proprietary Products, which sells mainly to drug companies, grew 12.6%, led by high-value components. West Vantage, the contract-manufacturing unit, fell 7.3%.

A $55.7 million gain on selling the SmartDose 3.5mL delivery system to AbbVie flattered the quarter's profit, and adjusted EPS was $2.66. The earnings release raised full-year net sales guidance to $3.41 billion to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48.

The Series C repayment is due on or about November 2, 2026, and the new term loan's first payment follows on March 31, 2028.

Sources

More on West Pharmaceutical

All West Pharmaceutical (WST) coverage →